The World Health Organization (WHO) has backed a Covid-19 treatment developed by Swiss pharmaceutical giant Roche and United States biotech company Regeneron.
This content was published on
2 minutes
swissinfo.ch/mga
Español
es
COVID-19: La OMS aprueba tratamiento Roche/Regeneron
WHO also made it clear that it wants both companies to make the treatment available to low income countries at an affordable price.
Roche and Regeneron have collaborated on producing the treatment using the monoclonal antibodies casirivimab and imdevimab, which have been shown to be effective at neutralising the virus when combined.
WHO on Friday recommended that the treatment be used on infected people who either have underlying health conditions or are suffering from severe symptoms.
The health body has urged both companiesExternal link to “address the high price and limited production” of the treatment. It is asking Roche for “a donation and distribution of the drug through UNICEF”.
The global health agency UNITAID is also negotiating with the manufacturers to grant access to the drug for less well-off countries.
“The need to have effective treatments for Covid-19 has never been greater, with many countries around the world facing case surges driven by Delta and other variants,” UNITAID stated on Friday. “These surges are having a particularly devastating impact on low- and middle- income countries, which continue to have limited access to vaccines.”
The agency welcomed an initial donation from Roche and Regeneron to meet this challenge but argued for a more sustainable solution. “Broader access commitments are needed from industry to ensure that pricing and supply conditions enable this product to reach all people regardless of where they live.”
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Chair of pharma firm Roche advocates mandatory Covid-19 vaccination
This content was published on
Christoph Franz said he was in favour of compulsory jabs if vaccination coverage rates were insufficient and if there was a social consensus.
Roche rheumatism drug does not reduce Covid-19 deaths
This content was published on
Swiss pharma firm Roche says a drug normally used to treat other medical conditions has failed to prove its effectiveness at alleviating the symptoms of Covid-19.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.